MedTrace Logo

Zoladex Plus Tamoxifen in Breast Cancer

NCT00827307 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2011-08-08

No results posted yet for this study

Summary

The purpose of this study is to compare Zoladex plus tamoxifen with tamoxifen alone as adjuvant hormonal therapy in pre- or perimenopausal women with early-stage breast cancer in terms of breast density, estrogen levels, lipidemia, endometrial thickness and ultrasonographic abnormalities.

Conditions

  • Mammography
  • Estrogen
  • Lipemia
  • Endometrium
  • Ultrasonography

Interventions

DRUG

tamoxifen

In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.

DRUG

Goserelin

In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Hong-Jian Yang, MD. · Zhejiang Provicial Cancer Hospital

  • Xiang-Yun Zong, MD., PhD. · Zhejiang Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00827307 on ClinicalTrials.gov